

Enrollment Form

Phone: 844-NEX-4321 (844-639-4321) • Fax: 844-232-2618

TO GET STARTED, COMPLETE THE ENROLLMENT FORM AND FAX IT TO 844-232-2618. PLEASE CHECK ALL BOXES THAT APPLY AND COMPLETE THE APPROPRIATE SECTION(S) OF THE FORM

Patient Benefit Investigation Prescription Order	
SPECIALTY PHARMACY ORDER	FOR ASSIGNMENT OF BENEFITS ONLY:
Please select one fulfillment option to indicate your preference. Note that Accredo Pharmacy AllianceRx Walgreens Prime CVS Health Pharmacy Humana Specialty Pharmacy	t some insurers may require use of a particular specialty pharmacy. ASPN Pharmacies, LLC Cigna Specialty Pharmacy Services Magellan Rx Pharmacy
PATIENT INFORMATION	
Last Name:	First Name:MI:
Date of Birth: F	Primary Language:
Address:	City: Zip Code:
Phone: Hom	e Cell Email:
Special Instructions:	
Current Medications:	
INSURANCE INFORMATION	
PLEASE COMPLETE ALL THAT APPLY AND INCLUDE A FRONT	AND BACK COPY OF INSURANCE CARD FOR EACH TYPE OF INSURANCE
Patient has no insurance and/or does not want insurance billed. Requests for	Self Pay option available at preferred Specialty Pharmacy.
Prescription Drug Card	Medical Insurance
Plan Name:	Plan Name:
Payer Phone:	Payer Phone:
PCN: Policy #: Group #:	
Policy Holder Information (If different from patient)	Policy Holder Information (If different from patient)
Name:	
Date of Birth:	
Relationship to Patient:	
Witter Processing # 107711 T-31 T-311	16, 910 (ANOTO TO 2004) (2004)

PATIENT AUTHORIZATION (REQUIRED if "Prescription Order" has been requested above)

I understand that in order for Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc., and Lash (the company that will conduct reimbursement services on behalf of Merck) to provide me with assistance, Lash and its administrators (collectively, "Lash") will need to obtain, review, use, and disclose my personal health information related to my treatment with NEXPLANON, information on my request form,

Patient name:	
i attetti name.	

PATIENT AUTHORIZATION (continued)

and any prescription for NEXPLANON® (etonogestrel implant) (my "PHI"). I authorize my physician, pharmacy(ies), and my health plan(s) to disclose my PHI to Lash as necessary to complete the insurance investigation process. I further authorize Lash and the Specialty Pharmacies (Accredo Pharmacy, AllianceRx Walgreens Prime, ASPN Pharmacies, LLC, Cigna Specialty Pharmacy Services, CVS Health Pharmacy, Humana Specialty Pharmacy, or Magellan Rx Pharmacy) and their respective affiliates to exchange my PHI to provide support and to disclose the information to my health plan(s) and their contractors for the purpose of coordination of benefits, reimbursement support, investigating insurance coverage and coordination of the delivery, receipt and storage of my prescription medication for NEXPLANON for the sole purpose of administration to me by my prescribing provider named above. I authorize the Specialty Pharmacy to use my PHI to contact me via mail, telephone, text, or email in connection with information related to this Enrollment Form. In order for the Specialty Pharmacy to ship my prescription medication for NEXPLANON directly to my prescribing provider, I authorize the Specialty Pharmacy to communicate with my prescribing provider about my PHI in order to coordinate the delivery, receipt, and storage of my prescription medication for NEXPLANON for the sole purpose of administration of my prescribing provider at my next scheduled appointment. I understand that my PHI disclosed pursuant to this Authorization may no longer be protected by certain federal privacy laws and may be re-disclosed by the recipient, but that Lash has agreed to use my PHI only for the purposes described herein.

I understand that if I do not sign this Authorization, that will not affect my receipt of treatment (including with NEXPLANON) or of health insurance benefits, but that I will not be able to obtain certain assistance provided by Lash on behalf of Merck. I understand that I may cancel this Authorization at any time by mailing a written request for such cancellation to Lash, PO Box 741, Monroeville, PA, 15146-0741. I understand that canceling my Authorization will not affect uses and disclosures of PHI already made in reliance on the Authorization before my cancellation is received by Lash.

If I do not cancel this Authorization, the Authorization will expire 12 months from the date signed below. Merck has retained Lash and the Specialty Pharmacies to provide support to customers, including reimbursement support. Information and questions related to the information provided in regard to this request should be referred directly to Lash. Merck personnel are not aware of patient-specific reimbursement information and are not permitted to discuss such information with customers. I have read this document or have had it explained to me. I understand that I may request a copy of this Authorization once it has been signed.

Patient Signature:	Date:
Print Name:	Date:
Relationship to patient if signing on their behalf:	Date:

If you have questions about completing this form or need additional information, please call 844-NEX-4321 (844-639-4321). Thank you.

PRESCRIPTION INFORMA	TION (REQUIR	ED if "Prescription Order" has been reque	ested)
Dispense: 1 Rx NEXPLANON* (etonogestrel implant) 68 mg	Days supplied: 3	_years Refills: _0_ Allergies:	
SIG: To be inserted one time by prescriber subdermally	Date of Last Menses:		
Anticipated Insertion Date:			
roduct Substitution Permitted (Signature)	Date	Dispense as Written (Signature)	Date
I certify that I have completed traini	ng for NEXPLANO!	N. If not certified, please contact your sales repr	esentative.
PRESCRIBER INFORMATION (prescrib	er or collab	orative physician must be trai	ned on NEXPLANON)
Name:			
Practice Name:			
ddress:			
tate: Zip Code: Tax ID #:			
PI#:			
		NPI #;	Date:
PRESCRIBER AUTHORIZATION			Date:
PRESCRIBER AUTHORIZATION MUST CONTAIN ORIGINAL SIGNATURE This request has been prepared exclusively by the physician or physician office request ("my Practice").	ce identified in this	requirements in my state. By submitting this Enro of benefit claims, the specialty pharmacy may shi	illment Form, I am aware that for assignment p product upon verification of benefits and
PRESCRIBER AUTHORIZATION MUST CONTAIN ORIGINAL SIGNATURE This request has been prepared exclusively by the physician or physician of fice request ("my Practice"). My Practice has obtained written authorization from the patient identified in disclose the patient's personal health information (PHI), including information	ce identified in this this request to n relating to the	requirements in my state. By submitting this Enro of benefit claims, the specialty pharmacy may shi collection of applicable co-pay. I understand that contacted.	allment Form, I am aware that for assignment p product upon verification of benefits and if there is no co-pay, the patient may not be
PRESCRIBER AUTHORIZATION MUST CONTAIN ORIGINAL SIGNATURE This request has been prepared exclusively by the physician or physician office request ("my Practice"). My Practice has obtained written authorization from the patient identified in disclose the patient's personal health information (PHI), including information patient's medical condition and prescription medications and the information Enrollment Form, as well as the information included in this request, to the Cu	this request to a relating to the disclosed in this ustomer Support	requirements in my state. By submitting this Enro of benefit claims, the specialty pharmacy may shi collection of applicable co-pay. I understand that contacted. • I understand that information concerning program statistical or other purposes and provided to Mer	allment Form, I am aware that for assignment product upon verification of benefits and if there is no co-pay, the patient may not be n participants may be summarized for ck and/or the CSCN.
PRESCRIBER AUTHORIZATION MUST CONTAIN ORIGINAL SIGNATURE This request has been prepared exclusively by the physician or physician offic request ("my Practice"). My Practice has obtained written authorization from the patient identified in disclose the patient's personal health information (PHI), including information patient's medical condition and prescription medications and the information	this request to relating to the disclosed in this ustomer Support .("Merck"), a heir contractors or	requirements in my state. By submitting this Enro of benefit claims, the specialty pharmacy may shi collection of applicable co-pay. I understand that contacted. • I understand that information concerning program	allment Form, I am aware that for assignment p product upon verification of benefits and if there is no co-pay, the patient may not be n participants may be summarized for ck and/or the CSCN. to conduct periodic audits of my Practice's excluding patient-identifiable data (unless the
PRESCRIBER AUTHORIZATION MUST CONTAIN ORIGINAL SIGNATURE This request has been prepared exclusively by the physician or physician office request ("my Practice"). My Practice has obtained written authorization from the patient identified in disclose the patient's personal health information (PHI), including information patient's medical condition and prescription medications and the information Enrollment Form, as well as the information included in this request, to the Concenter for NEXPLANON ("CSCN"), sponsored by Merck Sharp & Dohme Consubstidiary of Merck & Co., Inc., the administrators of the Program, including to other affiliates, and for the CSCN to use and disclose the information for the penelits investigation and reimbursement support. My Practice has provided the patient identified in this request with the notice comply with all federal and state laws and regulations relating to medical and including, but not limited to, the HIPAA Privacy Rule, codified at 45 C.F.R. Part	this request to a relating to the disclosed in this sustomer Support . ("Merck"), a heir contractors or purposes of the same state of the	requirements in my state. By submitting this Enro of benefit claims, the specialty pharmacy may shi collection of applicable co-pay. I understand that contacted. I understand that information concerning program statistical or other purposes and provided to Mer I understand that the Program reserves the right records to verify the information provided herein, auditor enters into an appropriate agreement with medical privacy). I consent to receive communications related to the I verify that the information provided is complete.	allment Form, I am aware that for assignment in product upon verification of benefits and if there is no co-pay, the patient may not be an participants may be summarized for ck and/or the CSCN. To conduct periodic audits of my Practice's excluding patient-identifiable data (unless that he Practice to protect an individual's see CSCN by telephone, email, and/or fax. and accurate to the best of my knowledge.
PRESCRIBER AUTHORIZATION MUST CONTAIN ORIGINAL SIGNATURE This request has been prepared exclusively by the physician or physician of fice request ("my Practice"). My Practice has obtained written authorization from the patient identified in disclose the patient's personal health information (PHI), including information patient's medical condition and prescription medications and the information Enrollment Form, as well as the information included in this request, to the Council Content for NEXPLANON ("CSCN"), sponsored by Merck Sharp & Dohme Corp subsidiary of Merck & Co., Inc., the administrators of the Program, including to other affiliates, and for the CSCN to use and disclose the information for the phenefits investigation and reimbursement support. My Practice has provided the patient identified in this request with the notice comply with all federal and state laws and regulations relating to medical and including, but not limited to, the HIPAA Privacy Rule, codified at 45 C.F.R. Part amended from time to time. If my patient is a minor, I certify that either 1) this patient's parent or guardian the patient's treatment with NEXPLANON (as allowable under the law of the practice), or 2) I, or a physician in my Practice, have determined that this patie capacity to consent to treatment with NEXPLANON under the law of the state.	this request to relating to the disclosed in this ustomer Support ("Merck"), a heir contractors or purposes of es necessary to d/or health privacy, is 160 and 164, as in has consented to state in which I ent has the	requirements in my state. By submitting this Enro of benefit claims, the specialty pharmacy may shi collection of applicable co-pay. I understand that contacted. I understand that information concerning program statistical or other purposes and provided to Mer I understand that the Program reserves the right records to verify the information provided herein, auditor enters into an appropriate agreement wit medical privacy). I consent to receive communications related to the I verify that the information provided is complete. I acknowledge the following: Merck has retained supplier of reimbursement support, to support the the information provided in response to the submit to Lash. Merck personnel are not aware of patien to discuss such information with customers. Com	allment Form, I am aware that for assignment product upon verification of benefits and if there is no co-pay, the patient may not be an participants may be summarized for ck and/or the CSCN. to conduct periodic audits of my Practice's excluding patient-identifiable data (unless that he Practice to protect an individual's see CSCN by telephone, email, and/or fax. and accurate to the best of my knowledge. Lash, a subsidiary of AmerisourceBergen, a c CSCN. Information and questions related to ission of this form should be referred directly t coverage information and are not permitted munications in response to this form will be
PRESCRIBER AUTHORIZATION MUST CONTAIN ORIGINAL SIGNATURE This request has been prepared exclusively by the physician or physician of fice request ("my Practice"). My Practice has obtained written authorization from the patient identified in disclose the patient's personal health information (PHI), including information patient's medical condition and prescription medications and the information patient Form, as well as the information included in this request, to the Conter for NEXPLANON ("CSCN"), sponsored by Merck Sharp & Dohme Corpsubsidiary of Merck & Co., Inc., the administrators of the Program, including to other affiliates, and for the CSCN to use and disclose the information for the phenefits investigation and reimbursement support. My Practice has provided the patient identified in this request with the notice comply with all federal and state laws and regulations relating to medical and including, but not limited to, the HIPAA Privacy Rule, codified at 45 C.F.R. Part amended from time to time. If my patient is a minor, I certify that either 1) this patient's parent or guardian the patient's treatment with NEXPLANON (as allowable under the law of the practice), or 2 1, or a physician in my Practice, have determined that this patie capacity to consent to treatment with NEXPLANON under the law of the state practice (and that consent of a parent or guardian is not required).	this request to relating to the disclosed in this usstomer Support ("Merck"), a heir contractors or purposes of es necessary to d/or health privacy, is 160 and 164, as in has consented to state in which I ent has the e in which I	requirements in my state. By submitting this Enro of benefit claims, the specialty pharmacy may shi collection of applicable co-pay. I understand that contacted. I understand that information concerning program statistical or other purposes and provided to Mer I understand that the Program reserves the right records to verify the information provided herein, auditor enters into an appropriate agreement wit medical privacy). I consent to receive communications related to the I verify that the information provided is complete. I acknowledge the following: Merck has retained supplier of reimbursement support, to support the information provided in response to the subm to Lash. Merck personnel are not aware of patient to discuss such information with customers. Comprepared for me by Lash, providing reimbursement pursuant to an agreement with Merck, in response	allment Form, I am aware that for assignment p product upon verification of benefits and if there is no co-pay, the patient may not be n participants may be summarized for ck and/or the CSCN. to conduct periodic audits of my Practice's excluding patient-identifiable data (unless the the Practice to protect an individual's ele CSCN by telephone, email, and/or fax. and accurate to the best of my knowledge. Lash, a subsidiary of AmerisourceBergen, a a CSCN. Information and questions related to ission of this form should be referred directly toverage information and are not permitted munications in response to this form will be it assistance services for Merck products et only request for insurance coverage
PRESCRIBER AUTHORIZATION MUST CONTAIN ORIGINAL SIGNATURE This request has been prepared exclusively by the physician or physician of fice request ("my Practice"). My Practice has obtained written authorization from the patient identified in disclose the patient's personal health information (PHI), including information patient's medical condition and prescription medications and the information Enrollment Form, as well as the information included in this request, to the Conter for NEXPLANON ("CSCN"), sponsored by Merck Sharp & Dohme Corp subsidiary of Merck & Co., Inc., the administrators of the Program, including to other affiliates, and for the CSCN to use and disclose the information for the phenefits investigation and reimbursement support. My Practice has provided the patient identified in this request with the notice comply with all federal and state laws and regulations relating to medical and including, but not limited to, the HIPAA Privacy Rule, codified at 45 C.F.R. Part amended from time to time. If my patient is a minor, I certify that either 1) this patient's parent or guardian the patient's treatment with NEXPLANON (as allowable under the law of the practice), or 2) I, or a physician in my Practice, have determined that this patie capacity to consent to treatment with NEXPLANON under the law of the state	this request to relating to the disclosed in this usstomer Support ("Merck"), a heir contractors or purposes of es necessary to d/or health privacy, is 160 and 164, as in has consented to state in which I ent has the e in which I ent has the e in which I enter the e	requirements in my state. By submitting this Enro of benefit claims, the specialty pharmacy may shi collection of applicable co-pay. I understand that contacted. I understand that information concerning program statistical or other purposes and provided to Mer I understand that the Program reserves the right records to verify the information provided herein, auditor enters into an appropriate agreement wit medical privacy). I consent to receive communications related to the I verify that the information provided is complete. I acknowledge the following: Merck has retained supplier of reimbursement support, to support the information provided in response to the subm to Lash. Merck personnel are not aware of patien to discuss such information with customers. Comprepared for me by Lash, providing reimbursement.	allment Form, I am aware that for assignment p product upon verification of benefits and if there is no co-pay, the patient may not be an participants may be summarized for ck and/or the CSCN. It to conduct periodic audits of my Practice's excluding patient-identifiable data (unless the the Practice to protect an individual's etc. and accurate to the best of my knowledge. Lash, a subsidiary of AmerisourceBergen, a ecscn. Information and questions related to ission of this form should be referred directly tooverage information and are not permitted munications in response to this form will be at assistance services for Merck products to my request for insurance coverage in provided will be based on statements of Merck. Neither Lash, the CSCN, nor Merck the accuracy of this information. Insurance variety of factors, including processing of coverage limits, changes in benefit design, and age information provided to me in response the ference only and does not guarantee currentival patient coverage information is provided.

Prescriber (please print): _ To report an adverse event for a specific Merck product, including death due to any cause, please contact the Merck National Service Center at 800-444-2080.

